DE69200794T2 - Use of 4,9,11-triene steroids in turkey compositions. - Google Patents
Use of 4,9,11-triene steroids in turkey compositions.Info
- Publication number
- DE69200794T2 DE69200794T2 DE69200794T DE69200794T DE69200794T2 DE 69200794 T2 DE69200794 T2 DE 69200794T2 DE 69200794 T DE69200794 T DE 69200794T DE 69200794 T DE69200794 T DE 69200794T DE 69200794 T2 DE69200794 T2 DE 69200794T2
- Authority
- DE
- Germany
- Prior art keywords
- trenbolone acetate
- compositions
- turkeys
- feed
- turkey
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title abstract description 6
- 241000286209 Phasianidae Species 0.000 claims abstract description 12
- CMRJPMODSSEAPL-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,14,15,16,17-octahydro-1h-cyclopenta[a]phenanthren-17-yl) acetate Chemical compound C1CC2=CC(=O)CCC2=C2C1C1CCC(OC(=O)C)C1(C)C=C2 CMRJPMODSSEAPL-UHFFFAOYSA-N 0.000 claims description 20
- 229960001332 trenbolone acetate Drugs 0.000 claims description 20
- 230000004584 weight gain Effects 0.000 abstract description 5
- 235000019786 weight gain Nutrition 0.000 abstract description 5
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 14
- 241000283690 Bos taurus Species 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/168—Steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/184—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Steroid Compounds (AREA)
- Fodder In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Feed For Specific Animals (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Die vorliegende Erfindung betrifft eine neue Verwendung van 4,9,11-Trien-Steroiden.The present invention relates to a new use of 4,9,11-triene steroids.
Die Erfindung hat die Verwendung van Trenbolonacetat bei Truthühnern zum Gegenstand und ist dadurch gekennzeichnet, daß das Trenbolonacetat in das Futter in einem Verhaltnis von 0,5 bis 10 ppm in Gewicht pro Gewicht Futter eingebracht wird.The invention relates to the use of trenbolone acetate in turkeys and is characterized in that the trenbolone acetate is introduced into the feed in a ratio of 0.5 to 10 ppm by weight per weight of feed.
Das Trenbolonacetat ist ein für seine anabolischen Eigenschaften bekanntes Produkt (vgl. Merck Index, 10.Auflage, Rubrik 9402).Trenbolone acetate is a product known for its anabolic properties (see Merck Index, 10th edition, section 9402).
Das Patent FR-A-2 168 207 beschreibt die Verabreichung von 4,9,11-Trien-Steroiden auf oralem Wege an Geflügel.Patent FR-A-2 168 207 describes the oral administration of 4,9,11-triene steroids to poultry.
Das Patent EP-A-0 272 976 sieht die Verabreichung von Trenbolonacetat in Kombination mit einem ß-adrenergischen Mittel auf oralem Wege an Tiere vor, insbesondere an Geflügel.Patent EP-A-0 272 976 provides for the administration of trenbolone acetate in combination with a ß-adrenergic agent by the oral route to animals, in particular to poultry.
Das Trenbolonacetat wurde bereits als Implantat an Truthühner verabfolgt [vgl. Maurice D.V. Jones et al., Nutr. Rep. Int. 31 (1), 1985, 59-66].Trenbolone acetate has already been administered as an implant to turkeys [cf. Maurice D.V. Jones et al., Nutr. Rep. Int. 31 (1), 1985, 59-66].
Es ist bekannt, daß das auf oralem Wege an verschiedene Tiere, insbesondere an Rinder verabreichte Trenbolonacetat nur eine relativ geringe Wirkung besitzt (vgl. A.G. Rico und V. Burgat-Sagaze in Anabolisants en Production Animale, Symposium, gehalten bei O.I.E. Paris 15,17 Februar 1983).It is known that trenbolone acetate administered orally to various animals, especially cattle, has only a relatively low effect (cf. A.G. Rico and V. Burgat-Sagaze in Anabolisants en Production Animale, Symposium held at O.I.E. Paris 15-17 February 1983).
Zu diesem Zweck wird das Trenbolonacetat in Form von Implantat, beispielsweise bei der Züchtung von Rindern, verwendet.For this purpose, Trenbolone acetate is used in the form of an implant, for example in cattle breeding.
Kürzlich wurde entdeckt, daß es möglich ist, herausragende Ergebnisse bei Truthühnern zu erhalten, indem man das Trenbolonacetat auf oralem Wege verabreicht, wie die Resultate der in der Anlage beigefügten biologischen Tests zeigen.Recently it has been discovered that it is possible to obtain outstanding results in turkeys by administering trenbolone acetate orally, as shown by the results of the biological tests attached in the appendix.
Die Verabreichung auf oral ein Wege vermeidet streßauslösende Manipulationen und ermöglicht die Anpassung der Dosierungen je nach Alter der Tiere im Moment der Behandlung.Oral administration avoids stress-inducing manipulations and allows the dosage to be adjusted according to the age of the animals at the time of treatment.
Außerdem wurde keine Nebenwirkung beobachtet:In addition, no side effects were observed:
- die plasmatischen Rückstande von TBA, beispielsweise bei 10, 12, 14, 16 und 18 Wochen sind niedriger als die Grenze der Dosierung;- the plasmatic residues of TBA, for example at 10, 12, 14, 16 and 18 weeks, are lower than the dosage limit;
- der Verlauf des Gehaltes an plasmatischer Transaminase (GOT und GPT) ist in bezug auf die Kontrolle nicht verändert.- the course of the plasma transaminase content (GOT and GPT) is not changed in relation to the control.
Weiterhin zeigen die Tiere keine Anomalie in ihrem lokomotorischen Verhalten.Furthermore, the animals show no abnormality in their locomotor behavior.
Die Erfindung hat spezieller die Verwendung zum Gegenstand, die dadurch gekennzeichnet ist, daß Trenbolonacetat in das Futter von Truthu-hnern in einem Verhältnis von 1 bis 4 ppm in Gewicht pro Gewicht Futter eingebracht wird.The invention more particularly relates to the use, characterized in that trenbolone acetate is incorporated into the feed of turkeys in a ratio of 1 to 4 ppm by weight per weight of feed.
Es wurden sehr gute Ergebnisse erhalten, indem man beispielsweise 0,2 bis 0,3 mg Trenbolonacetat pro Tag und pro Truthuhn ab der zehnten Woche der Behandlung verwendete, und insbesondere ein sehr guter Verbrauchsindex (IC), das heißt, das Verhältnis des Gesamtgewichtes an verbrauchtem Futter pro Tier zum Gesamt-Gewichtszuwachs, wie bei den als Anlage beigefügten Ergebnissen der biologischen Untersuchungen gezeigt wird.Very good results were obtained by using, for example, 0.2 to 0.3 mg of trenbolone acetate per day and per turkey from the tenth week of treatment, and in particular a very good consumption index (IC), that is to say the ratio of the total weight of feed consumed per animal to the total weight gain, as shown in the results of the biological tests attached as an annex.
Die folgenden Beispiele veranschaulichen die Erfindung ohne sie jedoch zu beschränken.The following examples illustrate the invention without, however, limiting it.
- Es wurden Zusammensetzungen hergestellt, die umfassen: Handelsübliches Futter, verkauft unter der Marke SANDERS (zweites Alter), zu dem man 2,5 ppm Trenbolonacetat gibt.- Compositions have been prepared comprising: Commercial feed sold under the brand SANDERS (second age) to which 2.5 ppm of trenbolone acetate is added.
- Es wurden Zusammensetzungen hergestellt, die 1,5 ppm Trenbolonacetat umfassen.- Compositions have been prepared containing 1.5 ppm Trenbolone Acetate.
- Es wurden Zusammensetzungen hergestellt, die 4 ppm Trenbolonacetat umfassen.- Compositions have been prepared containing 4 ppm Trenbolone Acetate.
Die Untersuchung wurde an weiblichen Truthühnern mit einem Alter von 10 Wochen durchgeführt.The study was conducted on female turkeys aged 10 weeks.
Die Tiere werden in zwei Gruppen aufgeteilt:The animals are divided into two groups:
- eine Kontrollgruppe von 37 Tieren,- a control group of 37 animals,
- eine Gruppe von 37 Tieren, die Trenbolonacetat im Futter erhalten.- a group of 37 animals receiving trenbolone acetate in their diet.
Die Truthühner erhalten eine zugeteilte Menge von Futter, die Trenbolonacetat umfaßt, und anschließend werden sie nach Belieben ernährt. Wirkung von Trenbolonacetat "per os" bei weiblichen Truthühnern Veränd Vorexperimentelle Periode Woche Kontrolle Behandelte Tiere Experimentelle Trenbolonacetat Truthenne PM = mittleres Gewicht in Gramm GPM = kumulierter Gewichtszuwachs %Veränd. = % Erhöhung des GPM der beh. Tiere in bezug auf die Kontrolle I.C. = Verbrauchs-Index Stat. = Test t: **signifik.Gewichtsunterschied bei 1 p 100, ***bei 1 p 1000The turkeys are given an allocated amount of feed containing trenbolone acetate and then fed ad libitum. Effect of trenbolone acetate "per os" in female turkeys Change Pre-experimental Period Week Control Treated animals Experimental Trenbolone acetate Turkeys PM = mean weight in grams GPM = cumulative weight gain %Change = % increase in GPM of treated animals compared to control IC = consumption index Stat. = test t: **significant weight difference at 1 p 100, ***at 1 p 1000
Man berechnet das mittlere Gewicht der Truthühner durch individuelles Wiegen in jeder Woche.The average weight of the turkeys is calculated by weighing them individually each week.
Man berechnet den Zuwachs des mittleren Gewichtes und den Verbrauchs-Index, das heißtThe increase in average weight and the consumption index are calculated, i.e.
Gesamtgewicht des dem Tier verabreichten Futters/Gesamt - GewichtszuwachsTotal weight of feed given to the animal/total weight gain
Die Ergebnisse sind in der vorstehenden Tabelle sowie in den als Anlage beigefügten Kurven zusammengefaßt.The results are summarized in the table above and in the curves attached as an appendix.
- Kurve 1 : Gewichtsverlauf bei weiblichen Truthühnern von 9 bis 19 Wochen;- Curve 1: Weight progression of female turkeys from 9 to 19 weeks;
- Kurve 2 : Verlauf der Differenz zwischen den kumulierten Verbrauchszahlen (Kontrolle - behandelte Tiere)- Curve 2: Course of the difference between the cumulative consumption figures (control - treated animals)
- Kurve 3 : Verlauf der Differenz zwischen dein mittleren Gewichtszuwachs der behandelten Tiere im Verhältnis zu den Kontrolltieren- Curve 3: Course of the difference between the mean weight gain of the treated animals in relation to the control animals
Claims (2)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9103777A FR2674436B1 (en) | 1991-03-28 | 1991-03-28 | NEW USE OF 4,9,11-TRIENIC STEROUIDES IN COMPOSITIONS FOR ADMINISTRATION IN TURKEY. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69200794D1 DE69200794D1 (en) | 1995-01-19 |
| DE69200794T2 true DE69200794T2 (en) | 1995-05-04 |
Family
ID=9411218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69200794T Expired - Fee Related DE69200794T2 (en) | 1991-03-28 | 1992-03-26 | Use of 4,9,11-triene steroids in turkey compositions. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0506565B1 (en) |
| JP (1) | JPH05117152A (en) |
| AT (1) | ATE114932T1 (en) |
| AU (1) | AU642814B2 (en) |
| CA (1) | CA2064358A1 (en) |
| CS (1) | CS84692A3 (en) |
| DE (1) | DE69200794T2 (en) |
| DK (1) | DK0506565T3 (en) |
| FR (1) | FR2674436B1 (en) |
| HU (1) | HUT61442A (en) |
| RU (1) | RU2067398C1 (en) |
| ZA (1) | ZA922249B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7229637B2 (en) | 1999-12-29 | 2007-06-12 | Sergei Mikhailovich Zenovich | Physiologically active agents containing vicinal dithioglycols and use thereof in various branches of economy |
| RU2158517C1 (en) * | 2000-02-25 | 2000-11-10 | Зенович Сергей Михайлович | Physiologically active agent for farm animals and poultry, method of preparation thereof, feed additive, and method of feeding animals and poultry |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1380414A (en) * | 1962-04-20 | 1964-12-04 | Roussel Uclaf | Novel estratriene steroids and method of preparation |
| BE794137A (en) * | 1972-01-20 | 1973-07-17 | Roussel Uclaf | POULTRY FOOD ADDITIVES AND CONTAINING FOOD COMPOSITIONS |
| IE60964B1 (en) * | 1986-12-11 | 1994-09-07 | Roussel Uclaf | Zootechnical compositions containing a beta-adrenergic |
-
1991
- 1991-03-28 FR FR9103777A patent/FR2674436B1/en not_active Expired - Fee Related
-
1992
- 1992-03-20 AU AU13071/92A patent/AU642814B2/en not_active Ceased
- 1992-03-20 CS CS92846A patent/CS84692A3/en unknown
- 1992-03-26 AT AT92400833T patent/ATE114932T1/en not_active IP Right Cessation
- 1992-03-26 JP JP4098599A patent/JPH05117152A/en not_active Withdrawn
- 1992-03-26 EP EP92400833A patent/EP0506565B1/en not_active Expired - Lifetime
- 1992-03-26 DK DK92400833.7T patent/DK0506565T3/en active
- 1992-03-26 HU HU9200931A patent/HUT61442A/en unknown
- 1992-03-26 DE DE69200794T patent/DE69200794T2/en not_active Expired - Fee Related
- 1992-03-27 RU SU925011205A patent/RU2067398C1/en active
- 1992-03-27 ZA ZA932249A patent/ZA922249B/en unknown
- 1992-03-27 CA CA002064358A patent/CA2064358A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HU9200931D0 (en) | 1992-05-28 |
| ZA922249B (en) | 1993-03-29 |
| HUT61442A (en) | 1993-01-28 |
| EP0506565B1 (en) | 1994-12-07 |
| JPH05117152A (en) | 1993-05-14 |
| CA2064358A1 (en) | 1992-09-29 |
| RU2067398C1 (en) | 1996-10-10 |
| FR2674436A1 (en) | 1992-10-02 |
| DK0506565T3 (en) | 1995-05-01 |
| ATE114932T1 (en) | 1994-12-15 |
| FR2674436B1 (en) | 1995-01-20 |
| EP0506565A1 (en) | 1992-09-30 |
| DE69200794D1 (en) | 1995-01-19 |
| AU642814B2 (en) | 1993-10-28 |
| CS84692A3 (en) | 1992-10-14 |
| AU1307192A (en) | 1992-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69822665T2 (en) | USE OF 9-DESOXY-2 ', 9-ALPHA-METHANO-3-OXA-4,5,6-TRINOR-3,7- (1', 3'-INTERPHENYLENE) -13,14-DIHYDROPROSTAGLANDIN-F1 FOR TREATMENT OF PERIPHERAL VASCULAR DISEASES | |
| DE3382641T2 (en) | MEDICINE FOR THERAPEUTIC TREATMENT OF ALOPEZIA. | |
| DE3019350C2 (en) | ||
| DE60012230T2 (en) | USE OF OLIGOSACCHARIDE-CONTAINING DERMATOLOGIC PREPARATION FOR THE TREATMENT OF SKIN DISEASES | |
| EP0185210B1 (en) | Use of dipeptide derivatives for the preparation of medicaments for the treatment of sufferers from amyotrophic lateral sclerosis | |
| EP0773022A2 (en) | Pharmaceutical composition for the treatment of rhinitus, containing sympathomometic and pantothenol and/or pantothenic acid | |
| DE3430799A1 (en) | METHOD FOR TREATING OSTEOPOROSIS | |
| DE2818586C2 (en) | ||
| DE3033545A1 (en) | USE OF KNOWN ANTIALLERGENIC AGENTS IN THE FIGHT AGAINST PATHOLOGICAL MINERAL RESORTION STATES | |
| DE3130912A1 (en) | ANALGETIC COMBINATION OF MEDICINAL PRODUCTS | |
| DE2617402C2 (en) | ||
| DE69023939T2 (en) | Promotion of osteogenesis through the use of vitamin D derivatives. | |
| CH676549A5 (en) | ||
| DE69200794T2 (en) | Use of 4,9,11-triene steroids in turkey compositions. | |
| DE2166355C2 (en) | Use of d, 1-sobrerol in balm therapy of the respiratory tract | |
| DE2916880C2 (en) | Medicines with sedative and sleep-inducing effects | |
| DE3780702T2 (en) | USE OF ETODOLAC TO REDUCE BLOOD CONTENT IN URIC ACID. | |
| DE2164988C3 (en) | 2,2-Diphenylcyclopropanecarboxylic acid ester derivatives, processes for their preparation and pharmaceuticals containing them | |
| DE1695043C2 (en) | Pharmaceutical compositions having sedative and tranquilizing properties | |
| EP0098475A2 (en) | Pharmaceutical composition, its manufacture and use | |
| DE69117943T2 (en) | TREATMENT OF ANIMALS | |
| DE2413803A1 (en) | PHARMACEUTICAL COMPOSITIONS OF MIXED SALT OF SULFOGLYCOPEPTIDES WITH METAL BASES AND ORGANIC BASES | |
| DE3239719T1 (en) | Uracil derivatives, processes for their preparation and pharmaceutical compositions containing the same | |
| DE1620177B2 (en) | N- (2-Hydroxyäthyl) -piperazinocarboxymethyl-te tr acy elin, its pharmacologically usable salts, processes for their preparation and medicaments containing these compounds | |
| DE2749075A1 (en) | QUATERNAERE 1-METHYL-2- (PHENOTHIAZIN- 10-YL) -AETHYLAMMONIUM SALTS AND MEDICINAL PRODUCTS CONTAINING THESE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |